Skip to content

Prospective Evaluation of PH-impedance Tracings According to the Wingate Consensus, and Influence on GERD Classification According to the Lyon Consensus

Prospective Evaluation of PH-impedance Tracings According to the Wingate Consensus, and Influence on Gastro-oesophageal Reflux Disease (GERD) Classification According to the Lyon Consensus.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06084572
Acronym
WinPro
Enrollment
120
Registered
2023-10-16
Start date
2023-09-29
Completion date
2026-04-01
Last updated
2025-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GERD

Keywords

GERD, pH-impedance, Wingate-consensus, Lyon consensus

Brief summary

Commonly, in clinical practice an automated analysis of pH-MII tracings is obtained.

Detailed description

All pH-MII performed in UZ Brussel are already reviewed manually according to the Wingate con-sensus and interpreted according to the Lyon consensus. In this study, we will prospectively categorise the reasons for discarding reflux episodes identified by automated analysis during the manual review according to the Wingate consensus, as well as the impact on different parameters related to the interpretation of pH-MII. Based on comments received to our retrospective study, we will evaluate possible confounders to the interpretation, including the indication for referral for pH-MII, symptom severity, use of PPI during pH-MII.

Interventions

OTHERQuestionnaires

FSSG & BEDQ

Sponsors

Universitair Ziekenhuis Brussel
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Adult patients aged 18 - 80 years old; * pH-MII performed off PPI

Exclusion criteria

* Prior upper GI endoscopy indicative of structural disease (except for oesophagitis or hiatal hernia). * Incomplete pH-MII (less than 21 hours recording); * Ph-MII performed on PPI * Suboptimal quality of the tracings preventing interpretation in clinical practice; * Prior oesophageal (including anti-reflux intervention) or gastric surgery.

Design outcomes

Primary

MeasureTime frameDescription
Statistical difference in the GERD categorisationDuring baseline visitthe statistical difference in the distribution of GERD categorisation between automated vs. manual review of the pH-MII tracings

Secondary

MeasureTime frameDescription
The analysis of the influence of different parameters on application of the Wingate criteria: including the GERD Symptom Severity;During baseline visit
The analysis of the influence of different parameters on application of the Wingate criteria: including the patient being on or off PPI;During baseline visit
The analysis of the influence of different parameters on application of the Wingate criteria: including MNBI (obtained by automated analysis or manually calculated);During baseline visit
The analysis of the influence of different parameters on application of the Wingate criteria: including the Indication for referral with further classification into predominant oesophageal and extra-oesophageal symptoms;During baseline visit
Impact of the Wingate criteria on The number of PSPW;During baseline visit
Impact of the Wingate criteria on The number of symptoms associated with an impedance episode.During baseline visit
Impact of the Wingate criteria on the number of impedance episodes with or without acidic refluxDuring baseline visit
Presence of significant correlations between censored episodes and pH-MII parametersDuring baseline visitCorrelations including: * Acid exposure time; * Total number of reflux episodes identified by impedance monitoring; * MNBI; * PSPWI.

Countries

Belgium, Germany

Contacts

Primary ContactSébastien Kindt, Prof. Dr.
sebastien.kindt@uzbrussel.be+32 2 477
Backup ContactVirgini Van Buggenhout
virgini.vanbuggenhout@uzbrussel.be+32 2 477

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026